ReviewPLoS pathogens2019
Roles, function and relevance of LAG3 in HIV infection.
Review in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer.Frontiers in immunology · 2024Review
- Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART.eLife · 2023Article
- Identification and in vitro and in vivo validation of the key role of GSDME in pyroptosis-related genes signature in hepatocellular carcinoma.BMC cancer · 2023Article
- Upregulation of LAG3 modulates the immune imbalance of CD4+ T-cell subsets and exacerbates disease progression in patients with alveolar echinococcosis and a mouse model.PLoS pathogens · 2023Article
- LAG-3 Contribution to T Cell Downmodulation during Acute Respiratory Viral Infections.Viruses · 2023Review
- Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2022Review
- Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people.JCI insight · 2022Article
- Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor.Cells · 2022Review
- Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells.PLoS pathogens · 2022Article
- The immune-suppressive landscape in lepromatous leprosy revealed by single-cell RNA sequencing.Cell discovery · 2022Article
- Analysis of Ferroptosis-Related LncRNAs Signatures Associated with Tumor Immune Infiltration and Experimental Validation in Clear Cell Renal Cell Carcinoma.International journal of general medicine · 2022Article
- Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Short Communication: Plasma Lymphocyte Activation Gene 3 and Subclinical Coronary Artery Disease in the Multicenter AIDS Cohort Study.AIDS research and human retroviruses · 2021Article
- Understanding LAG-3 Signaling.International journal of molecular sciences · 2021Review
- The immune landscape in tuberculosis reveals populations linked to disease and latency.Cell host & microbe · 2021Article
- Cytochalasins from Xylaria sp. CFL5, an Endophytic Fungus of Cephalotaxus fortunei.Natural products and bioprospecting · 2021Article
- A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1.Frontiers in immunology · 2021Article
- Deciphering DNA Methylation in HIV Infection.Frontiers in immunology · 2021Review
- Presence of Senescent and Memory CD8+ Leukocytes as Immunocenescence Markers in Skin Lesions of Elderly Leprosy Patients.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
HIV causes several forms of immune dysfunction that need to be addressed in a functional cure for HIV. Immune exhaustion describes a dysfunctional phenotype caused by chronic cellular activation. Lymphocyte activation gene-3 (LAG3) is one of several negative coreceptors known as immune checkpoints that contribute to this exhaustion phenotype. Antibodies targeting immune checkpoints are now used clinically to restore immunity against cancer and hold promise in restoring immunity during HIV infection. Here, we summarize current knowledge surrounding LAG3 and discuss its relevance during HIV infection and the potential for LAG3-targeting antibodies in a functional HIV cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.